Want to see PTHS full AI Analyst Report?
Total Valuation
Pelthos Therapeutics has a market cap or net worth of $84.95M. The enterprise value is $148.57.
Market Cap$84.95M
Enterprise Value$148.57
Share Statistics
Pelthos Therapeutics has 3,828,469 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,828,469
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Pelthos Therapeutics’s return on equity (ROE) is -1.11 and return on invested capital (ROIC) is -26.38%.
Return on Equity (ROE)-1.11
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-26.38%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee182.55K
Profits Per Employee-470.86K
Employee Count92
Asset Turnover0.13
Inventory Turnover0.40
Valuation Ratios
The current PE Ratio of Pelthos Therapeutics is ―. Pelthos Therapeutics’s PEG ratio is -0.02.
PE Ratio―
PS Ratio3.47
PB Ratio1.50
Price to Fair Value1.50
Price to FCF-2.57
Price to Operating Cash Flow-1.86
PEG Ratio-0.02
Income Statement
In the last 12 months, Pelthos Therapeutics had revenue of 16.80M and earned -43.32M in profits. Earnings per share was -23.04.
Revenue16.80M
Gross Profit7.43M
Operating Income-32.43M
Pretax Income-50.71M
Net Income-43.32M
EBITDA-45.41M
Earnings Per Share (EPS)-23.04
Cash Flow
In the last 12 months, operating cash flow was -42.30M and capital expenditures -295.00K, giving a free cash flow of -42.60M billion.
Operating Cash Flow-42.30M
Free Cash Flow-42.60M
Free Cash Flow per Share-11.13
Dividends & Yields
Pelthos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.63
52-Week Price Change-26.03%
50-Day Moving Average25.55
200-Day Moving Average25.04
Relative Strength Index (RSI)42.12
Average Volume (3m)41.84K
Important Dates
Pelthos Therapeutics upcoming earnings date is Nov 12, 2026, Before Open (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 12, 2026
Ex-Dividend Date―
Financial Position
Pelthos Therapeutics as a current ratio of 2.03, with Debt / Equity ratio of -4870.69%
Current Ratio2.03
Quick Ratio1.12
Debt to Market Cap0.55
Net Debt to EBITDA-0.37
Interest Coverage Ratio-10.77
Taxes
In the past 12 months, Pelthos Therapeutics has paid -7.39M in taxes.
Income Tax-7.39M
Effective Tax Rate0.15
Enterprise Valuation
Pelthos Therapeutics EV to EBITDA ratio is -1.65, with an EV/FCF ratio of -3.31.
EV to Sales4.47
EV to EBITDA-1.65
EV to Free Cash Flow-3.31
EV to Operating Cash Flow-3.32
Balance Sheet
Pelthos Therapeutics has $24.56M in cash and marketable securities with $73.11M in debt, giving a net cash position of -$48.55M billion.
Cash & Marketable Securities$24.56M
Total Debt$73.11M
Net Cash-$48.55M
Net Cash Per Share-$12.68
Tangible Book Value Per Share-$13.44
Margins
Gross margin is 54.72%, with operating margin of -193.09%, and net profit margin of -257.93%.
Gross Margin54.72%
Operating Margin-193.09%
Pretax Margin-301.91%
Net Profit Margin-257.93%
EBITDA Margin-270.37%
EBIT Margin-283.98%
Analyst Forecast
The average price target for Pelthos Therapeutics is $53.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$53.40
Price Target Upside99.40% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast―